NL-OMON30213已完成2 期
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - R129160 in patients with chronic idiopathic urticaria
Barrier Therapeutics0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subjects, male or female, aged between 18 and 65 (extremes included)
- •2. Confirmed diagnosis of CIU, with history of signs and symptoms for at least 3 days/week during more than 6 consecutive weeks in the 12 months preceding Visit 1, with active disease at the time of inclusion
- •3. During run-in period (from Visit 1 to Visit 2), pruritus and wheals present for at least 2 days
- •4. At least moderate pruritus (score of 2 or more) and wheals present (score of 1 or more) during the previous 12 hours
- •5. Ability to assess their symptom scores accurately and to complete the diary
- •6. Women of childbearing potential must have a negative urine pregnancy test at screening, must have used a highly effective stable form of birth control (with a failure rate of less than 1%) for at least one month prior to screening and must agree to remain on this effective form of birth control until the first menses after 30 days following the end of study medication treatment. This effective form of birth control consists of oral contraceptives or a contraceptive implant or a depot injection or a contraceptive patch or an IUD.
- •7. In addition, women of childbearing potential should use a double barrier method (one of the methods mentioned above under item 6 together with a condom and spermicidal agent or a diaphragm and spermicidal agent) from inclusion up to 7 days after end of treatment.
- •8. Availability of signed informed consent prior to beginning clinical trial protocol-specific procedures, indicating an understanding of the purpose of this trial and a willingness to adhere to the treatment regimen and trial procedures described in this clinical trial protocol
- •9. In good general health and free of any disease state or physical condition which, in the investigator*s opinion, exposes the subject to an unacceptable risk by trial participation
排除标准
- •1. Subjects with urticaria associated with a known underlying disease (eg Hodgkin disease, lupus erythematosus, hepatitis, vasculitis, hyperthyroidism), with physical urticaria (cold, heat, sun-induced, pressure or dermographism, aquagenic), with cholinergic urticaria, with hereditary angioedema or with urticaria due to medications, insect bites, food or any other known etiology
- •2. Subjects, previously unresponsive to at least two different antihistamines for the treatment of chronic idiopathic urticaria
- •3. History of drug allergy to antihistamines, other anti-allergic compounds, quinine or any of the components of the trial medication
- •4. History or suspicion of alcohol and/or drug abuse
- •5. Subjects having following concomitant disorders: significant hepatic, renal or bone marrow diseases, severe neuropathy including multiple sclerosis, significant psychiatric disorders or any other serious disease (including cancer and subjects known to be HIV positive), significant infection that requires systemic antibiotic treatment
- •6. Subjects previously randomized in the trial.
- •7. Any disease state or physical condition that, in the investigator*s opinion, may impair evaluation of itch and/or the urticaria, or may interfere with the treatment
- •8. Any disease state or surgery known to affect the GI absorption of drugs
- •9. Out-of-range laboratory test results that the investigator considers as pathologic
- •10. History of heart failure, myocardial infarction within the past six months, cardiac arrhythmia, or under treatment for heart disorders
- •11. Clinically significant abnormal ECG-intervals or morphology of the ECG; QT or QTc >470 ms in females or >450 ms in males
- •12. Use of following medication, unless discontinued at Visit 1: oral and/or topical antihistaminic compounds, including H2 antagonists (exception for Hismanal®: discontinued for at least 4 weeks before Visit 2); topical corticosteroids; topical immuno-modulating agents; other topical and/or systemic anti-allergic or anti-pruritic agents; non steroidal anti-inflammatory drugs (NSAIDs)
- •13. Use of sedatives or hypnotics within 7 days prior to Visit 1
- •14. Use of oral corticosteroids; oral immuno-modulating agents; antidepressants, antipsychotics or tranquillizers within 21 days prior to Visit 1
- •15. Use of intramuscular or intra-articular corticosteroids 90 days prior to Visit 1
- •16. Pregnant or breastfeeding women, or women of childbearing potential not using adequate contraceptives.
- •17. Received another investigational drug within the 30 days prior to entry into the trial
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-BEBarrier Therapeutics nv48
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-CZBarrier Therapeutics nv48
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-NLBarrier Therapeutics nv48
进行中（未招募）
1 期
An exploratory study of PQ Grass 27600 SEUCTR2020-000408-13-DEAllergy Therapeutics (UK) Ltd.150
进行中（未招募）
4 期
SPL7013 Nasal Spray safety and performance in patients with COVID-19ISRCTN70449927Starpharma (Australia)231